

ANTI-DRUGS POLICY

AMENDMENT HISTORY						
This document is reviewed periodically, at least annually, and is retained for a period of six years. Amendments and revisions are distributed by the named holder. The history of amendments and the issue of revisions are recorded below.						
ISS	REV	DESCRIPTION	PREPARED	APPROVED & AUTHORISED	SIGNED	ISSUE DATE
01	00	First Issue	David Wright	Marcel Madden Managing Director		01/09/2021
02	00	Policy Update	David Wright	Marcel Madden Managing Director		06/09/2022
03	00	Policy Review	David Wright	Marcel Madden Managing Director		26/01/2024

Disclaimer:	Although every care has been taken to ensure accuracy in the preparation of this Anti-Drugs Policy and subsequent updates, the Author, Dr D Wright shall not be liable for any misinterpretation, error, or omission by the reader, nor for incidental or consequential damage, including the violation of any General Data Protection Regulation and/or any associated legislation in connection with the use of this document.
Circulation List:	This Anti-Drugs Policy is a controlled document and is maintained on www.mydavidwright.co.uk as pdf read only. The Managing Director – Mr. M Madden must ensure that all amendments are circulated, and obsolete copies removed and filed. Hard copies used for training and internal auditing are controlled and distributed as follows.
Copy No:	1 (one) CONTROLLED
Holder:	Managing Director – Mr. Marcel Madden

 <p>Electrical Power Systems ▲ Modelling ▲ Analysis ▲ Design</p> <p>This document, including copyright and design rights, is the property of Delta Matrix Limited and may not be reproduced or used without the written permission of Delta Matrix Limited. It is supplied without liability for errors and or omissions. www.deltamatrix.co.uk</p>	TITLE	POLICY REF.		ISSUE
	ANTI-DRUGS POLICY	DML50004		03
	CONFIDENTIALITY LEVEL	ISSUE DATE	SHEET	REV
	CONTROLLED: UNCONTROLLED IF PRINTED	26/01/2024	1 of 4	00

1. Introduction

1.1. Delta Matrix Limited (hereafter referred to as “the Company”) are responsible employers and we take our obligations to our employees very seriously. Therefore, we have set out this policy to help us ensure the health, safety, and welfare of our employees and to help us comply with our legal duties.

- (a) Section 2(2)(e) of the Health and Safety at Work Act 1974 places a duty on employers to provide a safe and healthy working environment.
- (b) It is an offence to supply, produce, offer to supply, or produce controlled drugs.
- (c) The Misuse of Drugs Act 1971 makes it an offence for the occupier of premises to permit knowingly the production or supply of any controlled drugs or allow the smoking of cannabis or opium on those premises.
- (d) It is also an offence to aid or abet any of these offences.

1.2. This policy covers all employees, consultants, contractors, volunteers, and agency workers.

1.3. All employees and associates have a specific responsibility to operate within the boundaries of this policy, to ensure that all staff understand the standards of behaviour expected of them and to act when behaviour falls below its requirements.

1.4. Any reference in this Policy to a non-prescription drug refers only to controlled or illegal substances and does not refer to medicines, supplements and similar substances that are legally and commercially available in the United Kingdom.

2. Aims of the Policy

2.1. This Policy aims to:

- (a) comply with the Company’s legal obligations to provide a safe and healthy working environment for all staff.
- (b) comply with all the requirements imposed by law.
- (c) raise awareness of the effects of drug misuse and its likely symptoms.
- (d) ensure that employees are aware of their responsibilities regarding drug misuse and related problems; and
- (e) ensure that employees who have a drug-related problem affecting their work are dealt with sympathetically, fairly, and consistently.

3. Health and Safety

3.1. Misuse of drugs can lead to reduced levels of attendance, reduced efficiency, and performance, along with impaired judgement and decision-making. Employees should be aware that anyone under the influence of controlled drugs is a risk to everyone around them and should be alert to possible signs of drugs abuse. Such indicators commonly include:

- (a) sudden changes in behaviour.
- (b) confusion.
- (c) irritability.
- (d) fluctuations in mood and energy.

 <p>Electrical Power Systems • Modelling • Analysis • Design</p> <p><small>This document, including copyright and design rights, is the property of Delta Matrix Limited and may not be reproduced or used without the written permission of Delta Matrix Limited. It is supplied without liability for errors and omissions. www.deltamatrix.co.uk</small></p>	TITLE ANTI-DRUGS POLICY	POLICY REF. DML50004		ISSUE 03
	CONFIDENTIALITY LEVEL CONTROLLED: UNCONTROLLED IF PRINTED	ISSUE DATE 26/01/2024	SHEET 2 of 4	REV 00

- (e) impairment of performance; and
- (f) increase in short term sickness absence.

3.2. If employees notice a colleague displaying any or all these symptoms, employees should encourage them to seek assistance through the Company Managing Director. If they will not seek help themselves, employees should draw the matter to the attention of their manager. Employees should not, under any circumstances, discuss their concerns with any other colleagues.

3.3. If employees are prescribed medication, they must seek advice from their GP about the effect on their ability to carry out their job and whether duties should be modified. If so, employees should advise from the Company Managing Director immediately.

4. Searches

4.1. The Company reserves the right to conduct searches for drugs on Company premises including searches of desks, and any private lockers.

5. Prohibition

5.1. Employees are expected to arrive at work fit to carry out their job and to be able to perform their duties safely without limitations due to the use or after-effects of drugs. The use of drugs also includes the use of substances formerly known as “legal highs” or psychoactive drugs, which are legal substances which have the effect of illegal drugs.

5.2. No non-prescription drugs can be consumed in, or brought onto, company premises, land, or vehicles at any time by any person irrespective of their status in, or business with, the Company.

5.3. The prohibition of non-prescription drugs extends to all activities carried out by staff whilst they are at work. These activities include, but are not restricted to, driving on company business, when on call or standby duties or when on trips for company business, training, or social events.

6. Disciplinary Action

6.1. A breach of these rules will be defined as gross misconduct, and it is likely that the employee in question will face summary dismissal. If, however, an employee agrees to undertake appropriate treatment and/or rehabilitation for an acknowledged drug-related problem, the Company may decide to suspend any ongoing disciplinary action for related misconduct or poor performance pending the outcome of the treatment.

7. Principles

7.1. All information relating to an employee’s health including, but not limited to, matters involving drugs, will be collected, held, and processed in accordance with the Company’s Data Protection Policy.

7.2. If an employee is diagnosed as having a drug-related problem the Company will treat it as a health matter. This does not however excuse the employee from any of the disciplinary matters that may fall within the scope of the Company disciplinary policy.

7.3. Drug-related problems may develop for a variety of reasons and over a long period of time. All drug-related issues will be dealt with, as far as possible, in a constructive and sympathetic manner. The person responsible for all such issues in the Company is the

 <p>Electrical Power Systems • Modelling • Analysis • Design</p> <p><small>This document, including copyright and design rights, is the property of Delta Matrix Limited and may not be reproduced or used without the written permission of Delta Matrix Limited. It is supplied without liability for errors and or omissions. www.deltamatrix.co.uk</small></p>	TITLE	POLICY REF.		ISSUE
	ANTI-DRUGS POLICY	DML50004		03
	CONFIDENTIALITY LEVEL	ISSUE DATE	SHEET	REV
	CONTROLLED: UNCONTROLLED IF PRINTED	26/01/2024	3 of 4	00

Managing Director who will also provide employees with the details of where to seek further information and help.

7.4. All requests for help will be treated in the strictest confidence and all information gathered as a result will be held in accordance with the Company's Data Protection Policy. However, it must be recognised that, in supporting staff, some degree of information-sharing is likely to be necessary.

7.5. The Company reserves the right to give affected employees lighter duties at the same rate of pay or require them to take paid leave if it is deemed appropriate.

7.6. Following effective treatment and in the absence of any disciplinary action the Company will endeavour to return an affected employee to the same role previously fulfilled by the employee and, where this is not possible, to a suitable alternative.

7.7. If an employee following successful treatment for a drug related problem suffers a relapse, he/she will not make provision for any further treatment and the employee in question may face summary dismissal.

7.8. If it is considered that the working environment or culture is the cause or a contributor to a drug related problem, the Company will take all reasonably practicable steps to ensure a reduction of such problems.

This policy has been approved and authorised on behalf of Delta Matrix Limited by:



Marcel Madden BEng (Hons), CEng, DMS, MIET
Managing Director

 <small>Electrical Power Systems • Modelling • Analysis • Design</small> <small>This document, including copyright and design rights, is the property of Delta Matrix Limited and may not be reproduced or used without the written permission of Delta Matrix Limited. It is supplied without liability for errors and or omissions. www.deltamatrix.co.uk</small>	TITLE	POLICY REF.		ISSUE
	ANTI-DRUGS POLICY	DML50004		03
	CONFIDENTIALITY LEVEL	ISSUE DATE	SHEET	REV
	CONTROLLED: UNCONTROLLED IF PRINTED	26/01/2024	4 of 4	00